Novartis publishes long-term data from SMA gene therapy

Novartis publishes long-term data from SMA gene therapy

Source: 
Pharmaforum
snippet: 

Novartis has produced data demonstrating its Zolgensma gene therapy produces long term benefits in the rare muscle wasting disease spinal muscular atrophy – information that will be closely monitored by payers wanting a return on their investment in the world’s most expensive drug.